Related references
Note: Only part of the references are listed.Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
Raynier Devillier et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2021)
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Chemokine networks modulating natural killer cell trafficking to solid tumors
Xue Yao et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2021)
NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis
Sarah Nersesian et al.
TRANSLATIONAL ONCOLOGY (2021)
Tumor-Infiltrating Natural Killer Cells
Beatriz Cozar et al.
CANCER DISCOVERY (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Kate J. Dixon et al.
CANCERS (2021)
Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
Hyunsoo Cho et al.
CLINICAL CANCER RESEARCH (2021)
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
Chengxin Luo et al.
SCIENTIFIC REPORTS (2021)
Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy
Silvia Gaggero et al.
FRONTIERS IN IMMUNOLOGY (2021)
Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response
Elisa C. Toffoli et al.
CANCERS (2021)
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
Hyung-Seung Jin et al.
BMB REPORTS (2021)
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Emily J. Pomeroy et al.
MOLECULAR THERAPY (2020)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γc cytokine stimulation via PI3K/mTOR axis
Cristina Capuano et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Subhashis Sarkar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs
Alicia M. Chenoweth et al.
IMMUNOLOGY AND CELL BIOLOGY (2020)
NK Cell Function Regulation by TGF-β-Induced Epigenetic Mechanisms
Stefano Regis et al.
FRONTIERS IN IMMUNOLOGY (2020)
Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
Martin Villalba et al.
FRONTIERS IN IMMUNOLOGY (2020)
Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function
Gustavo Rodrigues Rossi et al.
FRONTIERS IN IMMUNOLOGY (2020)
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Aviad Ben-Shmuel et al.
FRONTIERS IN IMMUNOLOGY (2020)
Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms
Florian Cambay et al.
MOLECULAR IMMUNOLOGY (2020)
Overcoming hypoxia-induced functional suppression of NK cells
Kristen Solocinski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Mechanisms of Resistance to NK Cell Immunotherapy
Christian Sordo-Bahamonde et al.
CANCERS (2020)
Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis
Shuo Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives
Mir Mohd Faheem et al.
CELL DEATH DISCOVERY (2020)
The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies
Tobias Bald et al.
NATURE IMMUNOLOGY (2020)
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Keerthana Shankar et al.
STEM CELL RESEARCH & THERAPY (2020)
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles
Simona Caruso et al.
SEMINARS IN HEMATOLOGY (2020)
FcRγ Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells
Weiru Liu et al.
ISCIENCE (2020)
NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu
Stefanie Maurer et al.
FRONTIERS IN IMMUNOLOGY (2020)
Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance
Elisa Ferretti et al.
CANCERS (2020)
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity
Meisam Naeimi Kararoudi et al.
SEMINARS IN HEMATOLOGY (2020)
Natural killer cell engineering - a new hope for cancer immunotherapy
Cheng-Yu Lin et al.
SEMINARS IN HEMATOLOGY (2020)
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity
Brian C. Shaffer et al.
SEMINARS IN HEMATOLOGY (2020)
Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma
Won Jong Jin et al.
FRONTIERS IN IMMUNOLOGY (2020)
The cancer-natural killer cell immunity cycle
Nicholas D. Huntington et al.
NATURE REVIEWS CANCER (2020)
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
Hsiling Chiu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Targeting natural killer cells in solid tumors
Guillaume Habif et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Senescent cells: Living or dying is a matter of NK cells
Fabrizio Antonangeli et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy
Jianming Wu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders
Anca Prica et al.
LEUKEMIA & LYMPHOMA (2019)
Memory NK Cell Features Exploitable in Anticancer Immunotherapy
Cristina Capuano et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Magdalena Klanova et al.
CLINICAL CANCER RESEARCH (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Adaptive NK cells in people exposed to Plasmodium falciparum correlate with protection from malaria
Geoffrey T. Hart et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Mechanisms of natural killer cell-mediated cellular cytotoxicity
Isabel Prager et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9
Lukman O. Afolabi et al.
IMMUNOLOGY (2019)
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
Kristina Ellwanger et al.
MABS (2019)
IMiDs New and Old
Samuel Yamshon et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
Aura Muntasell et al.
CANCER IMMUNOLOGY RESEARCH (2019)
The Natural Cytotoxicity Receptors in Health and Disease
Alexander David Barrow et al.
FRONTIERS IN IMMUNOLOGY (2019)
Functional diversification of IgGs through Fc glycosylation
Taia T. Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
Monika Enqvist et al.
FRONTIERS IN IMMUNOLOGY (2019)
NK Cell Metabolism and Tumor Microenvironment
Inigo Terren et al.
FRONTIERS IN IMMUNOLOGY (2019)
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Carolyn Shembrey et al.
CANCERS (2019)
Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine
Sietse Q. Nagelkerke et al.
FRONTIERS IN IMMUNOLOGY (2019)
FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
Jode P. Goodridge et al.
BLOOD (2019)
NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection
Anita Schuch et al.
JOURNAL OF HEPATOLOGY (2019)
Phenotypic and Functional Analysis of Human NK Cell Subpopulations According to the Expression of FcεRIγ and NKG2C
Kyung Hwan Kim et al.
FRONTIERS IN IMMUNOLOGY (2019)
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Aura Muntasell et al.
CLINICAL CANCER RESEARCH (2019)
Glycoengineered antibodies: towards the next-generation of immunotherapeutics
Renato Mastrangeli et al.
GLYCOBIOLOGY (2019)
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Martin Felices et al.
BLOOD ADVANCES (2019)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
Natural killer cells target and differentiate cancer stem-like cells/undifferentiated tumors: strategies to optimize their growth and expansion for effective cancer immunotherapy
Kawaljit Kaur et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
Quirin Hammer et al.
NATURE IMMUNOLOGY (2018)
Natural killer cell specificity for viral infections
Quirin Hammer et al.
NATURE IMMUNOLOGY (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity
Lucas Ferrari de Andrade et al.
SCIENCE (2018)
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
Anna H. Turaj et al.
SCIENTIFIC REPORTS (2018)
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Vincent Yi Sheng Oei et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
Dhifaf Sarhan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming
Cristina Capuano et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
Hans H. Oberg et al.
FRONTIERS IN IMMUNOLOGY (2018)
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study
Shakeel Modak et al.
ONCOIMMUNOLOGY (2018)
ARID5B regulates metabolic programming in human adaptive NK cells
Frank Cichocki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells
Kristin M. Snyder et al.
FRONTIERS IN IMMUNOLOGY (2018)
Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues
Roberta Castriconi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Jan P. Boettcher et al.
TRENDS IN CANCER (2018)
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
Hyun Don Yun et al.
BLOOD ADVANCES (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
Acquired somatic mutations in PNH reveal long-term maintenance of adaptive NK cells independent of HSPCs
Marcus A. F. Corat et al.
BLOOD (2017)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2017)
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
Jesus I. Luna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl et al.
IMMUNOBIOLOGY (2017)
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
William C. Dougall et al.
IMMUNOLOGICAL REVIEWS (2017)
Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review
Tomonori Kaifu et al.
INTERNATIONAL IMMUNOLOGY (2017)
Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?
Josee Golay
JOURNAL OF AUTOIMMUNITY (2017)
Redefining Memory: Building the Case for Adaptive NK Cells
Silke Paust et al.
JOURNAL OF VIROLOGY (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis et al.
SEMINARS IN IMMUNOLOGY (2017)
Natural killer cell-mediated immunosurveillance of human cancer
Karl-Johan Malmberg et al.
SEMINARS IN IMMUNOLOGY (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells
Lisa L. Liu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Therapeutic Antibodies: What Have we Learnt from Targeting CD20 and Where Are We Going?
Michael J. E. Marshall et al.
FRONTIERS IN IMMUNOLOGY (2017)
Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production
Cristina Capuano et al.
ONCOIMMUNOLOGY (2017)
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Frank Cichocki et al.
CANCER RESEARCH (2017)
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Sara M. Federico et al.
CLINICAL CANCER RESEARCH (2017)
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Feng Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Victor A. Gall et al.
CANCER RESEARCH (2017)
Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies
Rut Valgardsdottir et al.
BLOOD (2017)
Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D
Zhongjuan Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells
Heinrich Schlums et al.
BLOOD (2017)
Targeting NK-cell checkpoints for cancer immunotherapy
Aura Muntasell et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ plus T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies
Letizia Muccio et al.
HAEMATOLOGICA (2016)
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Simone Battella et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
F. Cichocki et al.
LEUKEMIA (2016)
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+Colorectal Cancer Cells
J. U. Schmohl et al.
TARGETED ONCOLOGY (2016)
Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ plus T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies
Letizia Muccio et al.
HAEMATOLOGICA (2016)
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30
Christian Kellner et al.
ONCOIMMUNOLOGY (2016)
4-1BB agonism: adding the accelerator to cancer immunotherapy
Cariad Chester et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
Keith L. Knutson et al.
CANCER RESEARCH (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Erin M. Bertino et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
Joerg U. Schmohl et al.
MOLECULAR THERAPY (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Epigenetic Regulation of Adaptive NK Cell Diversification
Bianca Tesi et al.
TRENDS IN IMMUNOLOGY (2016)
Immune Adaptation to Environmental Influence: The Case of NK Cells and HCMV
Alexander Roelle et al.
TRENDS IN IMMUNOLOGY (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Asma Beldi-Ferchiou et al.
ONCOTARGET (2016)
Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
Joerg U. Schmohl et al.
ONCOTARGET (2016)
Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans
Lisa L. Liu et al.
CELL REPORTS (2016)
Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
Anna Maria Trotta et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2016)
Natural Regulators: NK Cells as Modulators of T Cell immunity
Iona S. Schuster et al.
FRONTIERS IN IMMUNOLOGY (2016)
Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases
Giovanni Bernardini et al.
FRONTIERS IN IMMUNOLOGY (2016)
A New Biological Feature of Natural Killer Cells: The Recognition of Solid Tumor-Derived Cancer Stem Cells
Rossana Tallerico et al.
FRONTIERS IN IMMUNOLOGY (2016)
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
Wei Hseun Yeap et al.
SCIENTIFIC REPORTS (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Natural killer cell memory in infection, inflammation and cancer
Adelheid Cerwenka et al.
NATURE REVIEWS IMMUNOLOGY (2016)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells
Cristina Capuano et al.
CANCER RESEARCH (2015)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
David J. DiLillo et al.
CELL (2015)
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors
Cariad Chester et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
Heinrich Schlums et al.
IMMUNITY (2015)
Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals
Jaewon Lee et al.
IMMUNITY (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
An NK Cell Population Lacking FcRγ Is Expanded in Chronically Infected HIV Patients
Jingling Zhou et al.
JOURNAL OF IMMUNOLOGY (2015)
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
David J. DiLillo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress
Meriem Hasmim et al.
FRONTIERS IN IMMUNOLOGY (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
Cariad Chester et al.
FRONTIERS IN IMMUNOLOGY (2015)
Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients
M. Christina Cox et al.
ONCOIMMUNOLOGY (2015)
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
Ronald P. Taylor et al.
BLOOD (2015)
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
Inger S. Nijhof et al.
HAEMATOLOGICA (2015)
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice
C. Deligne et al.
LEUKEMIA (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Balancing natural killer cell activation through paired receptors
Ludovic Martinet et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Mature Cytotoxic CD56(bright)/CD16(+) Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma
Meriem Messaoudene et al.
CANCER RESEARCH (2014)
Natural cytotoxicity receptors and their ligands
Philip H. Kruse et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion
Alexander Roelle et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
NK Cells Are Required for Dendritic Cell-Based Immunotherapy at the Time of Tumor Challenge
Anthea L. Bouwer et al.
JOURNAL OF IMMUNOLOGY (2014)
KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity
Grzegorz Terszowski et al.
JOURNAL OF IMMUNOLOGY (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients
Talib Hassan Ali et al.
NATURE COMMUNICATIONS (2014)
Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells
Merlin Luetke-Eversloh et al.
PLOS PATHOGENS (2014)
CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
Juan Du et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cancer-inducecd alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity
Anne-Sophie Chretien et al.
FRONTIERS IN IMMUNOLOGY (2014)
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Eric O. Long et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
Vivien Beziat et al.
BLOOD (2013)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D. Mellor et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency
Tianxiang Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
P. Glorius et al.
LEUKEMIA (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies
Ursula J. E. Seidel et al.
FRONTIERS IN IMMUNOLOGY (2013)
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?
Mariella Della Chiesa et al.
BLOOD (2012)
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
Bree Foley et al.
BLOOD (2012)
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Herve Ghesquieres et al.
BLOOD (2012)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naive T-cell subtypes
Ines Moeller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands
Wing Keung Chan et al.
CLINICAL CANCER RESEARCH (2012)
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients
Vivien Beziat et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O. Persky et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions
Ilwoong Hwang et al.
INTERNATIONAL IMMUNOLOGY (2012)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Regulation of Immune Responses by Prostaglandin E-2
Pawel Kalinski
JOURNAL OF IMMUNOLOGY (2012)
Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell-Tumor Cell Interactions
Jacques Deguine et al.
JOURNAL OF IMMUNOLOGY (2012)
Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen
Bree Foley et al.
JOURNAL OF IMMUNOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
Manfred Ahlgrimm et al.
BLOOD (2011)
Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus
Niklas K. Bjorkstrom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells
Jeffrey L. Wong et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
Sandra Lopez-Verges et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Riad Abes et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
Andrea Borgerding et al.
EXPERIMENTAL HEMATOLOGY (2010)
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a vaccinal effect of rituximab
Shannon P. Hilchey et al.
BLOOD (2009)
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
Siao-Yi Wang et al.
BLOOD (2009)
Functional and clinical consequences of Fc receptor polymorphic and copy number variants
S. Bournazos et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC
Atsushi Inagaki et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
Claudia Stolz et al.
LEUKEMIA & LYMPHOMA (2009)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
Ronald P. Taylor et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Emanuela Carlotti et al.
HAEMATOLOGICA (2007)
FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Zdravko Mitrovic et al.
HAEMATOLOGICA (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Activation, coactivation, and costimulation of resting human natural killer cells
Yenan T. Bryceson et al.
IMMUNOLOGICAL REVIEWS (2006)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts
M Gumá et al.
BLOOD (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Natural-killer cells and dendritic cells: l' union fait la force
T Walzer et al.
BLOOD (2005)
DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction
C Adam et al.
BLOOD (2005)
Activation of NK cell cytotoxicity
MJ Smyth et al.
MOLECULAR IMMUNOLOGY (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
A Martín-Fontecha et al.
NATURE IMMUNOLOGY (2004)
Imprint of human cytomegalovirus infection on the NK ceH receptor repertoire
M Gumá et al.
BLOOD (2004)
Regulation of perforin-independent NK cell-mediated cytotoxicity
RPA Wallin et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Natural killer cells activated by MHC class Ilow targets prime dendritic cells to induce protective CD8 T cell responses
R Mocikat et al.
IMMUNITY (2003)
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
E Cretney et al.
JOURNAL OF IMMUNOLOGY (2002)
Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific kill T cells dentritic cells
KM Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection
JM Kelly et al.
NATURE IMMUNOLOGY (2002)
CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
N Selenko et al.
LEUKEMIA (2001)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
K Imai et al.
LANCET (2000)
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
ML Disis et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Share Paper
